Nanocan Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$5M
- Investors
-
7
Nanocan Therapeutics General Information
Description
Developer of a novel drug-delivery nanotechnology designed for patients targeting certain solid cancer indications. The company's technology offers a sustained release of therapeutic agents, including immunotherapy, chemotherapy, and phytomedicines that enhance efficacy, minimize adverse effects, and optimize patient outcomes, enabling healthcare providers to deliver effective and accessible treatments to patients.
Contact Information
Website
www.nanocan.lifeCorporate Office
- 137 National Plaza
- Suite 300
- National Harbor, MD 20745
- United States
Corporate Office
- 137 National Plaza
- Suite 300
- National Harbor, MD 20745
- United States
Nanocan Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Seed Round | 12-Feb-2025 | $5M | Completed | Generating Revenue | ||
| 3. Grant | 09-May-2022 | Completed | Generating Revenue | |||
| 2. Seed Round | 23-Nov-2020 | $1.4M | $1.4M | Completed | Generating Revenue | |
| 1. Grant | 01-Jan-2020 | $1.2M | Completed | Generating Revenue |
Nanocan Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-1 | ||||||||
| Seed-2 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Nanocan Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Nanocan Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Nanocan Therapeutics Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AIN Ventures | Venture Capital | Minority | ||
| Alliance of Angels | Angel Group | |||
| Prevail Partners | Venture Capital | Minority | ||
| Sand Hill Angels | Angel Group | |||
| National Institutes of Health | Government |
Nanocan Therapeutics FAQs
-
When was Nanocan Therapeutics founded?
Nanocan Therapeutics was founded in 2020.
-
Where is Nanocan Therapeutics headquartered?
Nanocan Therapeutics is headquartered in National Harbor, MD.
-
What is the size of Nanocan Therapeutics?
Nanocan Therapeutics has 9 total employees.
-
What industry is Nanocan Therapeutics in?
Nanocan Therapeutics’s primary industry is Drug Delivery.
-
Is Nanocan Therapeutics a private or public company?
Nanocan Therapeutics is a Private company.
-
What is the current valuation of Nanocan Therapeutics?
The current valuation of Nanocan Therapeutics is .
-
What is Nanocan Therapeutics’s current revenue?
The current revenue for Nanocan Therapeutics is .
-
How much funding has Nanocan Therapeutics raised over time?
Nanocan Therapeutics has raised $6.4M.
-
Who are Nanocan Therapeutics’s investors?
AIN Ventures, Alliance of Angels, Prevail Partners, Sand Hill Angels, and National Institutes of Health are 5 of 7 investors who have invested in Nanocan Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
